A business with a wide economic moat, a Piotroski score of 9 out of 9, and 16% margins trades at a forward multiple of 6.1x with a PEG of 0.05 — implying the market is deeply discounting a franchise with durable return characteristics; the setup is held back by three earnings misses in the last four quarters and a sole-product revenue base that amplifies any execution stumble.
Thesis pillars
- Wide Moat Bargain Valuation→Stable
- Single Product Sole Source Concentration→Stable
- Earnings Miss Pattern Risk→Stable
- +1 more pillar — see the Why tab for full reasoning
Harmony Biosciences Holdings, I (HRMY) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Wait for pullback to $34.57. At $36.29 the A.R:R is 0.4:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $34.57 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: WAKIX; Concentration risk — Supplier: sole-source suppliers and manufacturers.
Harmony Biosciences commercializes WAKIX (pitolisant), the only FDA-approved non-scheduled narcolepsy treatment, cleared for excessive daytime sleepiness and cataplexy in adult and pediatric patients. WAKIX generated $868.5 million in net product revenue in fiscal 2025 from a... Read more
Wait for pullback to $34.57. At $36.29 the A.R:R is 0.4:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $34.57 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: WAKIX; Concentration risk — Supplier: sole-source suppliers and manufacturers. Chart setup: Golden cross, above all MAs, RSI 68, MACD bullish. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.04, quality 7.8/10, growth 8.3/10). Score 6.7/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news boost analyst 0.40, earnings proximity 29d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
Recent developments
updated 2026-07-07Recent Developments — Harmony Biosciences Holdings, I
Latest news
- NEWS Harmony Biosciences to Participate in Upcoming Investor Conferences - Business Wire — Business Wire neutral
- NEWS Harmony Biosciences to Participate in Upcoming Investor Conferences - Yahoo Finance — Yahoo Finance neutral
- NEWS H.C. Wainwright reiterates Harmony Biosciences stock rating at buy - Investing.com — Investing.com positive
- NEWS Oppenheimer raises Harmony Biosciences stock price target on patent strength - Investing.com UK — Investing.com UK positive
- NEWS Harmony Biosciences (HRMY) Is Up 9.7% After New CFO Hire And Reiterated 2026 Guidance – Has The Bull Case Changed? - sim — simplywall.st positive
Generated 2026-07-07T11:31:43Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductWAKIX10-K Item 1A: 'we expect the sales of WAKIX to generate substantially all of our revenue for the foreseeable future'
- HIGHSuppliersole-source suppliers and manufacturers10-K Item 1A: 'We rely completely on third parties to manufacture and distribute our supply of WAKIX and our product candidates, including certain sole-source suppliers and manufacturers'
- HIGHSupplierBioprojet license10-K Item 1A: 'We rely on our license agreements with Bioprojet to provide rights to the core intellectual property relating to pitolisant'
Material Events(8-K, last 90d)
- 2026-04-14Item 5.02MEDIUMCFO Sandip Kapadia stepped down effective April 14, 2026 to pursue other career opportunities. Glenn Reicin appointed as successor CFO effective the same day.SEC filing →
- 2026-04-02Item 5.02LOWPeter Anastasiou appointed Senior EVP and COO effective April 2, 2026. In connection with appointment, resigned as Class III board director effective same date. No disagreement with Company or Board cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $34.57. At $36.29 the A.R:R is 0.4:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $34.57 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: WAKIX; Concentration risk — Supplier: sole-source suppliers and manufacturers. Chart setup: Golden cross, above all MAs, RSI 68, MACD bullish. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.04, quality 7.8/10, growth 8.3/10). Target $39.07 (+7.7%), stop $32.47 (−11.8%), A.R:R 0.4:1. Score 6.7/10, moderate confidence.
Take-profit target: $39.07 (+11.1% upside). Target $39.07 (+7.7%), stop $32.47 (−11.8%), A.R:R 0.4:1. Stop-loss: $32.47.
Concentration risk — Product: WAKIX; Concentration risk — Supplier: sole-source suppliers and manufacturers; Thin upside margin: 5.6%.
Harmony Biosciences Holdings, I trades at a P/E of 15.0 (forward 6.2). TrendMatrix value score: 8.3/10. Verdict: Buy (Wait for Entry).
17 analysts cover HRMY with a consensus score of 3.8/5. Average price target: $45.
What does Harmony Biosciences Holdings, I do?Harmony Biosciences commercializes WAKIX (pitolisant), the only FDA-approved non-scheduled narcolepsy treatment,...
Harmony Biosciences commercializes WAKIX (pitolisant), the only FDA-approved non-scheduled narcolepsy treatment, cleared for excessive daytime sleepiness and cataplexy in adult and pediatric patients. WAKIX generated $868.5 million in net product revenue in fiscal 2025 from a U.S. narcolepsy market valued at approximately $3.1 billion. The company holds an exclusive U.S. license from Bioprojet and relies entirely on third-party contract manufacturers, including certain sole-source suppliers.